Business
Arno Therapeutics Reports First Quarter 2016 Financial and Business Update
Arno Therapeutics Reports First Quarter 2016 Financial and Business Update.
About this update from Arno Therapeutics Inc
[{"type":"text","content":"\nFLEMINGTON, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, today announced financial results for the quarter ended March 31, 2016 and provided an update on recent clinical developments for its lead compound, onapristone.  \nQ1 2016 and Recent Highlights:Continued to actively enroll patients in the second stage of its Phase I/II trial of onapristone in men with advanced, castration-resistant prostate cancer (CRPC) who have failed treatment with abiraterone or enzalutamide. The Phase II portion of this study will evaluate onapristone in combination with Zytiga® (abiraterone acetate) in patients with CRPC.Formed Prostate Cancer Advisory Board chaired by Stuart Holden, MD, a Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology Associate Director, and Institute of Urologic Oncology at the UCLA David Geffen School of Medicine, to oversee the prostate study evaluating onapristone in combination with Zytiga® (abiraterone acetate) in patients with CRPC. Executed strategic decision to focus its resources on its prostate cancer program and close the onapristone Phase II study of patients with recurrent or metastatic endometrioid cancer. The decision to close the Phase II endometrioid cancer study was not based on any safety or lack of efficacy signal and the Company will continue to provide onapristone to all patients currently enrolled in this trial on a compassionate use basis. “Based on emerging scientific evidence, we determined that the most effective clinical path forward was to focus on our CRPC program, as that was the indication for which onapristone held the greatest potential. Along with this strategic shift, we have formed a world-class Prostate Cancer Advisory Board, chaired by Dr. Stuart Holden, who is joined by a group of preeminent thought leaders in the genitourinary oncology/steroid receptor area. Our Phase I/II study of onapristone in men with advanced CRPC who have failed treatment with abiraterone or enzalutamide is progressing according to plan. We look forward to the advancement of the trial, including enrollment of additional subjects and bringing our U.S. sites on-board. We are confident that this is...